In addition, targeted treatments for other genetic variations in NSCLC are currently under development, including RET fusion [11], human epidermal growth factor receptor 2 (HER2) insertion (NCT04382300), or MET exon 14 skipping mutations (NCT02897479). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.